Oct

22

Diabetes

Filed Under Biotechnology & Drugs | Leave a Comment

Diabetes is the world’s fastest-growing disease. It is responsible for a QUARTER of all deaths in many parts of the world. (Many more people die from diabetes than AIDS.)

But every so often, something wonderful comes along that changes the lives of millions of people. It is called: Pulse Insulin Therapy, and hundreds of thousands of people will be given new lives.

Never before has a single small public company played so dominant a role in the birth of such a large “industry.” This small public company, Diabetic Treatment Centers of America (Symbol: DBTC) offers this new product called Pulse Insulin Theraphy (PIT). PIT treatment will permit hundreds of thousands of patients to live again. As only diabetics can truly know what that means. Thus, Diabetic Treatment Centers of America is presenting itself as a rare opportunity for early investors.

Who is Diabetic Treatment Centers of America?
Diabetic Treatment Centers of America offers a true breakthrough in diabetes treatment: Pulse Insulin Therapy (PIT). Recently approved for reimbursement by Medicare and major insurance companies, PIT is the only treatment available that can effectively slow, stop and reverse the chronic complications associated with diabetes. Diabetic Treatment Centers of America is the only public company pioneering this advance, in the world’s fastest-growing industry.

What Pulse Insulin Therapy DOES…
PIT is the first effective treatment that actually stops and even reverses the terrible complications, returning a diabetic to a more normal life. A diabetic visits a clinic for three one-hour treatments over a six hour period, sits in a chair attached to an IV, along with the Bionica pump and a RQ apparatus. The Bionica pump mimics that particular patient’s liver needs, to reestablish the ability to metabolize carbohydrates. Meanwhile the RQ equipment measures the precise carbohydrate and lipid metabolic levels. This monitors how well the body is regaining normality. The patient returns once a week. Within a few weeks, the patient should start noticing a difference. Within a few months his metabolism should be restored to near normal, and the diabetic deterioration will slow, stop and even reverse itself.

Now diabetics can lead normal lives with the greatest FDA-approved breakthrough in over 80 years! Complications from this terrible disease can now be stopped — even reversed! This diabetes ‘miracle’ is also creating a virgin multi-billion dollar industry — and a rare opportunity for early investors.

What’s so special about PIT?
• A diabetic person’s metabolism can now be restored to roughly equal that of a healthy non-diabetic. For the first time, the liver — targeted by the insulin — can now open enzymatic pathways and allow cells to receive and process normal carbohydrates (glucose). This increases a patient’s energy almost immediately!

• People confined to wheelchairs are actually walking again. People with advanced neuropathy facing amputations can actually REVERSE their condition. People with circulatory disease can now work again, and people with the common type of damaged hearts can be “repaired.” (Source: allpennystocks.com)

Here are the recent news about this company:

Diabetic Treatment Centers of America, Inc. Announces Clinic Site in Utah
http://biz.yahoo.com/bw/041021/215097_1.html
Thu 8:30am – Business Wire

Diabetic Treatment Centers of America, Inc. Announces Clinic Site in Utah
http://biz.yahoo.com/prnews/041020/law121_1.html
Wed, Oct 20 – PR Newswire

Patented Technology, Focused Growth, Growing Demand — Arden Oliphant, CEO of Diabetic Treatment Centers of America Inc., Talks with Traders Nation
http://biz.yahoo.com/bw/041020/205896_1.html
Wed, Oct 20 – Business Wire

For the past 3 months, the stock has been performing really well. It went up from $0.7/share to $1.22/share. This might be a good time for you to invest in this company. This is more a long-term investment – since the product has just gotten approved and the company is still trying market the product.

Quote of the Day:
If we command our wealth, we shall be rich and free; if our wealth commands us, we are poor indeed. – A leading efficient market theorist

  • Share/Bookmark

Oct

12

DNAPrint Genomics Inc. (Symbol: DNAP)

Filed Under Biotechnology & Drugs | Leave a Comment

Last week I just purchased 3,000 shares of DNAPrint Genomic Inc. (Symbol: DNAG). Didn’t really cost me a lot of money since it’s traded around 1 cents/share. Want to know why did I invest in this company? Well…Let me tell you a little bit information about this company.

DNAPrint Genomic Inc. is a genomics science company, focusing on the sale of unique proprietary genetic testing products and services. They are currently focusing their efforts in four distinct markets:
1. Pharmacogenomics Market
The testing of individuals to predict their genetic predisposition to drug response is known as pharmacogenomics. Pharmacogenomics enables physicians to tailor drug therapies (formulation and dosage) for individuals based on their genetic composition, increasing rates of therapeutic success and decreasing rates of adverse side effects. Drug discovery companies are beginning to use pharmacogenomics technologies to develop drugs that are suitable for subpopulations based upon their genetic composition.

2. Forensics DNA Testing Market
Testing DNA to create a physical profile of crime suspects is a new market based on evolving technologies. Common hereditary traits such as skin pigmentation, eye color, hair color, earlobe attachment and height can be predicted through analysis of DNA sequences. DNAPrintTM believes it is the first company to use DNA evidence to successfully profile a crime suspect by predicting that suspect’s continental origin.

3. Consumer DNA Products Market
There is an established market of consumers who recreationally research their genealogy and ancestral origin. Additionally, there is a market for paternity tests and other tests related to lineage. DNAPrintTM serves both of these consumer market segments through direct sales and independent distributors.

4. Contract Service Outsourcing Market
DNAPrintTM provides universities and drug discovery companies with genotyping services. The service provides our clients with the ability to screen efficiently and effectively for genes that may be responsible for certain human traits and/or disease states. (Source: http://www.dnaprint.com/)

Currently the share is traded at $0.015/share, which is unbelievably cheap. Obviously this is more like long-term investment since there are not a lot of companies are doing this technology yet. If you’re still not convinced that this company is a good investment, check out these news releases:

1. DNAPrint(TM) genomics, Inc. Agrees to Acquire Majority Ownership in German Pharmaceutical Company Biofrontera AG; Secures $35 Million Equity Commitment from Dutchess Private Equities Fund, L.P.
http://www.biospace.com/news_story.cfm?StoryID=17515920&full=1

2. DNAPrint Presents Forensics Discoveries; New Products Could Transform The Landscape Of DNA Testing
http://www.dnaprint.com/pr_6_27.htm

3. DNAPrint launches ‘ethnicity’ test
http://www.drugresearcher.com/news/news-NG.asp?id=54499

Quote of the Day:
If we find a company we like, the level of the market will not really impact our decisions. We will decide company by company. We spend essentially no time thinking about macroeconomic factors. – Warren Buffett

  • Share/Bookmark

← Previous Page